Paul Gilbert joins the SMC Growth Capital Partners II Strategic Advisory Board
NEWS PROVIDED BY
Spring Mountain Capital
February 21, 2019
We are pleased to announce the appointment of Paul Gilbert to the SMC Growth Capital Partners II Strategic Advisory Board. Our partnership with Paul began during the time that he was the Co-Founder and CEO of MedAvante, a former Fund I portfolio company.
We are excited about this new partnership and look forward to his contributions to further support our Fund II portfolio C-suite.
Paul Gilbert has 30 years of leadership, strategy, and innovation experience at best-practice organizations including Johnson & Johnson, Arm & Hammer, Booz Allen and Gillette. He has successfully scaled up companies in both consumer and business markets with an emphasis on innovating new markets.
As CEO of MedAvante, Paul and his co-founder, Amy Ellis, envisioned, launched, and globalized two new-to-world innovations that transformed psychiatric and neurological trials across a 40 country footprint. The first, Central Ratings, solved the pharmaceutical industry’s intractably high rate of failed mental health trials. MedAvante reduced trial failure rates of known effective psychiatric treatments from 50% to under 15%. The second innovation, electronic clinical outcome assessments (eSource), led the pharma industry’s transition from error-prone paper-based central nervous system trials to accurate digitally-enabled trials. This innovation achieved $200 million sales in its first 32 months. At the time of MedAvante’s sale, Paul’s GlassDoor rating was 98% versus the eHealth category average of 51%.
Paul has served most recently on the boards of Growth Philanthropy Network (current), Derma Sciences, a publicly traded tissue regeneration company recently acquired, and the prestigious non-profit International Longevity Centre Global Alliance (acquired by Columbia University). Paul has been invited to present on innovation multiple times at Princeton, Wharton, and Stanford and is a strategic advisor to young innovative companies. In 2012, he was awarded the Ernst & Young Lifesciences Entrepreneur of the Year.
Paul graduated magna cum laude from Bowdoin College where he was named a James Bowdoin Scholar, and received his MBA from Harvard University.